| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Readnour Robin Shane is a Director at AN2 Therapeutics, Inc.. Recent SEC Form 4 filings include 16 buys and 4 sells.
Estimated insider holdings value: $48K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 10, 2024 | ANTX An2 Therapeutics, Inc. | Director | Buy | 60,000 | $1.45 | $86,708.01 | +1.7% | -10.6% | -21.9% | |
| Nov 27, 2024 | ANTX An2 Therapeutics, Inc. | Director | Buy | 75,000 | $1.41 | $105,685.00 | +3.4% | -19.0% | -20.4% | |
| Nov 20, 2024 | ANTX An2 Therapeutics, Inc. | Director | Buy | 200,000 | $1.07 | $213,127.50 | +10.3% | -12.3% | -16.9% | |
| Jan 12, 2024 | ANTX An2 Therapeutics, Inc. | Director | Sell | 1,425 | $21.91 | $31,228.81 | -0.2% | -85.6% | -94.0% | |
| Jan 10, 2024 | ANTX An2 Therapeutics, Inc. | Director | Sell | 3,669 | $21.93 | $80,443.17 | -0.4% | -85.4% | -94.0% | |
| Mar 29, 2022 | ANTX An2 Therapeutics, Inc. | Director | Buy | 153,334 | $15.00 | $2,300,010.00 | +20.4% | -44.1% | -34.6% |